Concord Biotech Announces 1:1 Bonus Issue and Capital Expansion

Paid-up share capital will rise to Rs 20.92 crore following the issuance. Authorized share capital increases from Rs 11 crore to Rs 22 crore.

Reader Takeaway: Bonus issues increase share liquidity, though the market price adjusts proportionally on the ex-date.

What just happened

Concord Biotech’s Board of Directors has formally approved a 1:1 bonus issue. This means existing shareholders will receive one additional fully paid-up equity share of Rs 1 each for every single share held on a yet-to-be-announced record date. The company will utilize Rs 10.46 crore from its existing share premium account—which held Rs 81.97 crore as of March 31, 2026—to fund this expansion.

Why this matters

The bonus issue is a move to improve liquidity and equity base reach. By doubling the number of total shares from approximately 10.46 crore to 20.92 crore, the company aims to make its stock more accessible to retail investors. Simultaneously, the board has approved increasing the authorized share capital to Rs 22 crore, ensuring adequate headroom for these new shares and potential future capital requirements.

What changes now

Investors currently holding Concord Biotech shares should note that these actions are subject to shareholder approval. The company expects the entire process to be finalized within two months, by November 22, 2026. Because this involves an amendment to the Memorandum of Association, formal shareholder voting is a mandatory next step.

What to track next

The most critical information pending is the 'Record Date.' This date will be determined by the board and formally communicated to the stock exchanges. Only shareholders appearing on the company's register of members as of the record date will be eligible for the bonus shares. The stock price will also undergo a mechanical adjustment on the ex-date to reflect the expanded share count.